Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1755237 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $3.50Day +0.00%Mkt cap $15M1Y +32.6%Off 52W high −58.7%Vol (1Y) 330.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,837 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.8% of sh out |
| Days to cover1.3d |
| 13F net flow (QoQ)+0.83% |
| Top-10 13F concentration99.8% |
| Next report (est.)2026-08-19 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$2.0M |
| Earnings (TTM)-$5.3M |
| ROE−39.3% |
| Net margin−170.1% |
| ROIC−68.5% |
| Sales growth 3Y91.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+175.6% |
| 1Y+32.6% |
| 3Y+9.5% |
| 5Y−94.0% |
| Since incept. (ann.)−45.3% |
Total return through 2026-07-30 · series begins 2019-04-02. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)330.1% |
| Ann. volatility (3Y)280.3% |
| Sharpe (1Y)0.75 |
| Sharpe (3Y)0.68 |
| Max drawdown (1Y)−66.8% |
| Max drawdown (3Y)−83.0% |
| Beta (3Y vs SPY)1.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 84,550 | $129,800 | 1.95% | +95.3% |
| CITADEL ADVISORS LLC | 18,261 | $28,031 | 0.42% | new |
| BlackRock, Inc. | 16,797 | $26,035 | 0.39% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 16,137 | $24,770 | 0.37% | new |
| Kovack Advisors, Inc. | 10,000 | $15,500 | 0.23% | new |
| VANGUARD FIDUCIARY TRUST CO | 7,353 | $11,287 | 0.17% | new |
| FMR LLC | 4,740 | $7,276 | 0.11% | +0.0% |
| UBS Group AG | 3,391 | $5,256 | 0.08% | +801.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.76 | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-30 | — | — | $1.0M | −43.2% |
| 2025-09-30 | 2025-11-12 | −$0.30 | — | $875,000 | +351.0% |
| 2025-06-30 | 2025-08-05 | −$0.11 | — | $93,000 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-19 is ESTIMATED from filing cadence (median gap 99d) — not company-confirmed.
